Reading a deficiency letter: what FDA is actually asking

A deficiency letter is not a rejection. It is the agency telling you, in writing and in order, exactly what stands between your submission and a decision. Sponsors who read it that way answer it once. Sponsors who read it as a verdict answer it three times.

First, know which letter you’re holding. FDA’s letters are not interchangeable, and the response clock is different for each.

For an IDE, the agency must act within 30 days of receipt, and there are three outcomes. Approval means the study may begin. Approval with conditions means the study may begin, but the conditions listed must be addressed — typically within 45 days — or the approval lapses. Disapproval means the study may not begin until the deficiencies listed are resolved through an IDE amendment, which restarts the 30-day clock. An Early Feasibility Study runs under the same framework, with the additional flexibility described in FDA’s EFS guidance about what can be resolved during the study rather than before it.

For a 510(k), the equivalent is an Additional Information request. The review clock stops, and you have 180 days to respond. Miss it and the submission is treated as withdrawn.

For a PMA, a major deficiency letter stops the review clock and typically carries a 180-day window; the response is a formal amendment.

The letter names its own type. Read that line before anything else, because it sets the deadline, the format of the response, and the consequence of getting it wrong.

Second, separate the deficiencies from everything else. A deficiency letter mixes three kinds of content: numbered deficiencies, which are the items you must resolve; observations and recommendations, which the reviewer wants you to see but which don’t block a decision; and administrative notes about format and process. Sponsors routinely spend effort on the second category while under-answering the first. Build a table on day one: every numbered deficiency, verbatim, in the agency’s own order, with a column for your response and a column for the supporting evidence you’ll attach.

Third, read each deficiency for the question behind it. FDA reviewers write deficiencies in a constrained, formal register, and the literal text often understates what’s being asked. “Please provide the rationale for the selection of the pre-specified endpoint” is rarely a request for a paragraph — it is usually a signal that the reviewer doesn’t believe the endpoint is clinically meaningful for the indication, or that the timepoint is too early to show it. The useful question is not “what does this sentence ask for?” but “what would make the reviewer stop asking?” If you cannot tell, that is what interactive review is for: a call with the lead reviewer to clarify the intent of a deficiency is routine, appropriate, and far cheaper than guessing.

Fourth, answer in the agency’s structure, not yours. The response restates each deficiency verbatim, numbered as in the letter, followed by the response and a reference to where the supporting material sits in the amendment. Reviewers are reading dozens of these. A response that makes them hunt for the answer to deficiency 7 is a response that gets a second deficiency letter. The cover letter summarizes what changed and why, in a page. It is not the place to argue.

Fifth, decide what you will not concede. Some deficiencies are right. Some rest on a misreading of your submission. Some ask for evidence that is disproportionate to the risk. You can push back — respectfully, with reasoning, and with an alternative — and a well-argued disagreement is taken seriously. But choose those battles deliberately. A response that contests every point reads as a sponsor who hasn’t understood the letter.

Sixth, treat the letter as a map of the review. The deficiencies tell you which sections the reviewers read most closely and where their concerns concentrate. That is information about the rest of your program: the clinical protocol, the pivotal design, the eventual marketing application. The best sponsors update their regulatory strategy after every letter, not just their submission.

A deficiency letter is the most direct communication you will receive from FDA about your device. Read it as instruction, answer it as a dialogue, and it becomes the shortest path to a decision.